Literature DB >> 32866582

Maresin1 ameliorates sepsis-associated lung injury by inhibiting the activation of the JAK2/STAT3 and MAPK/ NF-κB signaling pathways.

Fuquan Wang1, Min Wang2, Jingxu Wang1, Ming Chen1, Shujun Sun1, Shanglong Yao3, Haifa Xia4.   

Abstract

Sepsis-associated acute lung injury (ALI) is a clinically critical disease that carries a high mortality rate. The pathogenesis of sepsis-associated ALI has not yet been precisely elucidated and there is a lack of effective treatment. As a new endogenous docosahexaenoic acid (DHA)-derived lipid mediators, Maresin1 has a significant dual role of anti-inflammatory and promoting inflammation regression. In this study, we established the sepsis model by the cecal ligation and puncture method (CLP) to explore the effect of Maresin1 on sepsis-induced lung injury. We found that the intervention of Maresin1 could significantly attenuate the sepsis-induced inflammatory responses, characterized by the down-regulation of the level of IL-1β, IL-6, TNF-α, MPO, etc. Maresin1 could also significantly decrease the number of neutrophils in lung tissue, thus improving the related lung injury indicators. Our experiment clarified that the protective effect of Maresin1 on sepsis-associated lung injury is closely related to its inhibition function of JAK2/STAT3 and MAPK/NF-κB signaling pathways. Our findings provide new research directions and therapeutic targets for sepsis-associated ALI.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  JAK2; MAPK; Maresin1; NF-κB; STAT3; Sepsis

Mesh:

Substances:

Year:  2020        PMID: 32866582     DOI: 10.1016/j.micpath.2020.104468

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  8 in total

1.  Isoorientin suppresses sepsis-induced acute lung injury in mice by activating an EPCR-dependent JAK2/STAT3 pathway.

Authors:  Mu Hu; Jielai Yang; Yang Xu
Journal:  J Mol Histol       Date:  2021-11-17       Impact factor: 2.611

2.  Long noncoding RNA MIR3142HG accelerates lipopolysaccharide-induced acute lung injury via miR-95-5p/JAK2 axis.

Authors:  Yanqiu Gao; Shuangfeng Li; Rui Dong; Xiaoyan Li
Journal:  Hum Cell       Date:  2022-03-11       Impact factor: 4.374

3.  OGDH is involved in sepsis induced acute lung injury through the MAPK pathway.

Authors:  Yuewei Hao; Zheng Wang; Xinfang Wang; Wenming Zhan; Dianshui Wu
Journal:  J Thorac Dis       Date:  2021-08       Impact factor: 2.895

4.  Detecting Critical Functional Ingredients Group and Mechanism of Xuebijing Injection in Treating Sepsis.

Authors:  Qi- Wu; Chuan-Hui Yin; Yi Li; Jie-Qi Cai; Han-Yun Yang; Ying-Ying Huang; Yi-Xu Zheng; Ke Xiong; Hai-Lang Yu; Ai-Ping Lu; Ke-Xin Wang; Dao-Gang Guan; Yu-Peng Chen
Journal:  Front Pharmacol       Date:  2021-12-06       Impact factor: 5.810

5.  Systematic identification of the interventional mechanism of Qingfei Xiaoyan Wan (QFXYW) in treatment of the cytokine storm in acute lung injury using transcriptomics-based system pharmacological analyses.

Authors:  Jing-Yi Hou; Jia-Rong Wu; Yi-Bing Chen; Dong Xu; Shu Liu; Dan-Dan Shang; Guan-Wei Fan; Yuan-Lu Cui
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.503

6.  Maresin1 Protect Against Ferroptosis-Induced Liver Injury Through ROS Inhibition and Nrf2/HO-1/GPX4 Activation.

Authors:  Wenchang Yang; Yaxin Wang; Chenggang Zhang; Yongzhou Huang; Jiaxian Yu; Liang Shi; Peng Zhang; Yuping Yin; Ruidong Li; Kaixiong Tao
Journal:  Front Pharmacol       Date:  2022-04-04       Impact factor: 5.988

7.  Exosomal hsa_circRNA_104484 and hsa_circRNA_104670 may serve as potential novel biomarkers and therapeutic targets for sepsis.

Authors:  Chang Tian; Jiaying Liu; Xin Di; Shan Cong; Min Zhao; Ke Wang
Journal:  Sci Rep       Date:  2021-07-08       Impact factor: 4.379

8.  Protective effect of taurine on sepsis‑induced lung injury via inhibiting the p38/MAPK signaling pathway.

Authors:  Jiao Chen; Xiang Xue; Jianqin Cai; Ling Jia; Baodi Sun; Wei Zhao
Journal:  Mol Med Rep       Date:  2021-07-19       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.